Mutual of America Capital Management LLC Sells 3,924 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Mutual of America Capital Management LLC cut its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 5.5% during the third quarter, Holdings Channel reports. The institutional investor owned 67,187 shares of the biotechnology company’s stock after selling 3,924 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Arrowhead Pharmaceuticals were worth $1,301,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in Arrowhead Pharmaceuticals by 16.2% in the 1st quarter. Vanguard Group Inc. now owns 12,404,050 shares of the biotechnology company’s stock valued at $354,756,000 after buying an additional 1,731,974 shares during the period. CANADA LIFE ASSURANCE Co raised its position in Arrowhead Pharmaceuticals by 9.8% in the first quarter. CANADA LIFE ASSURANCE Co now owns 90,571 shares of the biotechnology company’s stock worth $2,589,000 after purchasing an additional 8,065 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Arrowhead Pharmaceuticals by 17.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 71,136 shares of the biotechnology company’s stock worth $2,035,000 after purchasing an additional 10,568 shares during the period. Silvercrest Asset Management Group LLC boosted its holdings in Arrowhead Pharmaceuticals by 49.9% during the first quarter. Silvercrest Asset Management Group LLC now owns 150,198 shares of the biotechnology company’s stock valued at $4,296,000 after purchasing an additional 49,972 shares in the last quarter. Finally, Bayesian Capital Management LP bought a new stake in shares of Arrowhead Pharmaceuticals in the 1st quarter valued at approximately $724,000. 62.61% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals Price Performance

ARWR stock opened at $18.79 on Tuesday. The stock has a market capitalization of $2.34 billion, a PE ratio of -4.02 and a beta of 0.93. The company has a 50 day moving average price of $19.82 and a 200 day moving average price of $23.17. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $17.05 and a fifty-two week high of $39.83.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Royal Bank of Canada reiterated an “outperform” rating and set a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Thursday, September 26th. StockNews.com raised shares of Arrowhead Pharmaceuticals to a “sell” rating in a report on Tuesday, November 12th. Piper Sandler restated an “overweight” rating and issued a $62.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, October 8th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arrowhead Pharmaceuticals in a report on Monday, September 9th. Finally, HC Wainwright reissued a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $45.33.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.